Beijing Tiantan Biological Products Corp Ltd (600161) - Total Liabilities
Based on the latest financial reports, Beijing Tiantan Biological Products Corp Ltd (600161) has total liabilities worth CN¥1.60 Billion CNY (≈ $234.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 600161 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Beijing Tiantan Biological Products Corp Ltd - Total Liabilities Trend (1995–2024)
This chart illustrates how Beijing Tiantan Biological Products Corp Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Beijing Tiantan Biological Products Corp asset portfolio.
Beijing Tiantan Biological Products Corp Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Tiantan Biological Products Corp Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Valin Steel Co Ltd
SHE:000932
|
China | CN¥85.27 Billion |
|
Jiangxi Hongdu Aviation Industry Co Ltd
SHG:600316
|
China | CN¥10.94 Billion |
|
Hinge Health, Inc.
NYSE:HNGE
|
USA | $366.23 Million |
|
Olav Thon Eien
OL:OLT
|
Norway | Nkr32.70 Billion |
|
New Hope Corporation Ltd
AU:NHC
|
Australia | AU$894.41 Million |
|
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
|
USA | $25.40 Million |
|
QL Resources Bhd
KLSE:7084
|
Malaysia | RM2.47 Billion |
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NYSE:AMRX
|
USA | $2.78 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Beijing Tiantan Biological Products Corp Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Beijing Tiantan Biological Products Corp balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Tiantan Biological Products Corp Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Tiantan Biological Products Corp Ltd (1995–2024)
The table below shows the annual total liabilities of Beijing Tiantan Biological Products Corp Ltd from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.34 Billion ≈ $195.55 Million |
-6.79% |
| 2023-12-31 | CN¥1.43 Billion ≈ $209.79 Million |
-9.51% |
| 2022-12-31 | CN¥1.58 Billion ≈ $231.84 Million |
+20.87% |
| 2021-12-31 | CN¥1.31 Billion ≈ $191.81 Million |
-13.20% |
| 2020-12-31 | CN¥1.51 Billion ≈ $220.97 Million |
+32.81% |
| 2019-12-31 | CN¥1.14 Billion ≈ $166.39 Million |
+57.88% |
| 2018-12-31 | CN¥720.19 Million ≈ $105.39 Million |
+49.59% |
| 2017-12-31 | CN¥481.46 Million ≈ $70.45 Million |
-85.59% |
| 2016-12-31 | CN¥3.34 Billion ≈ $489.08 Million |
-1.57% |
| 2015-12-31 | CN¥3.40 Billion ≈ $496.90 Million |
-10.59% |
| 2014-12-31 | CN¥3.80 Billion ≈ $555.74 Million |
+9.82% |
| 2013-12-31 | CN¥3.46 Billion ≈ $506.05 Million |
+14.17% |
| 2012-12-31 | CN¥3.03 Billion ≈ $443.22 Million |
+70.36% |
| 2011-12-31 | CN¥1.78 Billion ≈ $260.16 Million |
+36.14% |
| 2010-12-31 | CN¥1.31 Billion ≈ $191.10 Million |
+7.76% |
| 2009-12-31 | CN¥1.21 Billion ≈ $177.34 Million |
+175.83% |
| 2008-12-31 | CN¥439.35 Million ≈ $64.29 Million |
+18.96% |
| 2007-12-31 | CN¥369.34 Million ≈ $54.05 Million |
+3.69% |
| 2006-12-31 | CN¥356.20 Million ≈ $52.12 Million |
+98.25% |
| 2005-12-31 | CN¥179.67 Million ≈ $26.29 Million |
+42.93% |
| 2004-12-31 | CN¥125.70 Million ≈ $18.39 Million |
-21.06% |
| 2003-12-31 | CN¥159.24 Million ≈ $23.30 Million |
-26.18% |
| 2002-12-31 | CN¥215.73 Million ≈ $31.57 Million |
+24.24% |
| 2001-12-31 | CN¥173.64 Million ≈ $25.41 Million |
+4.12% |
| 2000-12-31 | CN¥166.77 Million ≈ $24.40 Million |
+4.31% |
| 1999-12-31 | CN¥159.88 Million ≈ $23.40 Million |
+42.06% |
| 1998-12-31 | CN¥112.54 Million ≈ $16.47 Million |
+73.47% |
| 1997-12-31 | CN¥64.88 Million ≈ $9.49 Million |
-11.20% |
| 1996-12-31 | CN¥73.06 Million ≈ $10.69 Million |
+12.10% |
| 1995-12-31 | CN¥65.18 Million ≈ $9.54 Million |
-- |
About Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamin… Read more